Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma


Study Number
56917
Phase
1
Purpose

This is a Phase 1, multi-center, open-label study of TRPH-222 monotherapy in subjects with relapsed and/or refractory B-cell NHL. The study will be conducted in two Stages: Dose-Escalation, Dose-Expansion.

Full Title

Phase 1, Multicenter, Open-Label Study of the Antibody-Drug Conjugate TRPH-222 in Subjects with Relapsed and/or Refractory B Cell Lymphoma

ClinicalTrials.Gov ID
NCT03682796

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.